Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse Who Are Eligible for High Dose Treatment Followed by Autologous Peripheral Blood Stem Cell Transplantation (ASCT)

Next Previous
Trial Profile

Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse Who Are Eligible for High Dose Treatment Followed by Autologous Peripheral Blood Stem Cell Transplantation (ASCT)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Cisplatin; Cytarabine; Dexamethasone; Dexamethasone
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HOVON/LLPC Transplant BRaVE study; Transplant BRaVE

Most Recent Events

  • 01 Dec 2022 Results assessing prognostic value of serum (s)TARC, vitamin D and lactate dehydrogenase (LDH), TARC immunohistochemistry and quantitative PET parameters published in the Leukemia
  • 17 Jun 2021 Results of long-term follow-up and biomarker analysis assessing biomarkers relapsed/refractory hodgkin lymphoma patients presented at the 26th Congress of the European Haematology Association
  • 09 Apr 2021 This trial has been completed in Denmark, according to European Clinical Trials Database record. (Global end date: 2020-10-23).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top